$ATXI
Avenue Therapeutics Inc Stock $atxi

$atxi Overview Financials Valuation SEC Filings Company Website

2024 Q1 Form 10-K Financial Statement

#000143774924008294 Filed on March 18, 2024

Income Statement

Concept	2024 Q1	2023 Q4	2023
Revenue	$0.00	$0.00	$0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$1.316M	$1.137M	$4.179M
YoY Change	33.74%	-66.23%	-21.81%
% of Gross Profit
Research & Development	$2.392M	$982.0K	$6.131M
YoY Change	96.87%	227.33%	127.24%
% of Gross Profit
Depreciation & Amortization
YoY Change
% of Gross Profit
Operating Expenses	$2.392M	$2.119M	$6.131M
YoY Change	96.87%	606.33%	127.24%
Operating Profit	-$3.708M		-$14.54M
YoY Change	-42.32%		80.78%
Interest Expense	$49.00K	$22.00K	-$206.0K
YoY Change	-104.18%	-99.5%	-104.64%
% of Operating Profit
Other Income/Expense, Net	-$641.0K	$2.714M	$4.258M
YoY Change	-45.35%	-51.36%	-23.69%
Pretax Income	-$4.349M	$617.0K	-$10.49M
YoY Change	-42.79%	17.75%	191.09%
Income Tax			$0.00
% Of Pretax Income
Net Earnings	-$4.349M	$640.0K	-$10.49M
YoY Change	-42.79%	11.3%	195.27%
Net Earnings / Revenue
Basic Earnings Per Share	-$15.40		-$0.98
Diluted Earnings Per Share	-$7.72	$0.03	-$0.98
COMMON SHARES
Basic Shares Outstanding	44.26M	13.25M	10.59M
Diluted Shares Outstanding

Balance Sheet

Concept	2024 Q1	2023 Q4	2023
SHORT-TERM ASSETS
Cash & Short-Term Investments	$3.194M	$1.783M	$1.783M
YoY Change	-61.22%	-73.42%	-73.42%
Cash & Equivalents	$3.194M	$1.783M	$1.783M
Short-Term Investments
Other Short-Term Assets	$116.0K	$67.00K	$67.00K
YoY Change	-41.41%	-51.09%	-51.09%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets	$3.310M	$1.850M	$1.850M
YoY Change	-60.81%	-72.97%	-72.97%
LONG-TERM ASSETS
Property, Plant & Equipment
YoY Change
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets	$0.00	$0.00	$0.00
YoY Change
TOTAL ASSETS
Total Short-Term Assets	$3.310M	$1.850M	$1.850M
Total Long-Term Assets	$0.00	$0.00	$0.00
Total Assets	$3.310M	$1.850M	$1.850M
YoY Change	-60.81%	-72.97%	-72.97%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$662.0K	$78.00K	$78.00K
YoY Change	100.61%	-39.53%	-76.85%
Accrued Expenses	$337.0K	$532.0K	$532.0K
YoY Change	-92.6%	-15.96%	-15.96%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$1.412M	$1.196M	$1.196M
YoY Change	-86.68%	-66.58%	-66.58%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$0.00
YoY Change
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities	$0.00	$0.00	$0.00
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities	$1.412M	$1.196M	$1.196M
Total Long-Term Liabilities	$0.00	$0.00	$0.00
Total Liabilities	$1.412M	$1.196M	$268.0K
YoY Change	-86.68%	-66.58%	-90.88%
SHAREHOLDERS EQUITY
Retained Earnings	-$95.30M	-$90.90M
YoY Change	8.17%	12.78%
Common Stock	$0.00	$3.000K
YoY Change	-100.0%	-100.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$2.836M	$1.582M	$1.582M
YoY Change
Total Liabilities & Shareholders Equity	$3.310M	$1.850M	$1.850M
YoY Change	-60.81%	-72.97%	-72.97%

Cashflow Statement

Concept	2024 Q1	2023 Q4	2023
OPERATING ACTIVITIES
Net Income	-$4.349M	$640.0K	-$10.49M
YoY Change	-42.79%	11.3%	195.27%
Depreciation, Depletion And Amortization
YoY Change
Cash From Operating Activities	-$3.120M	-$2.324M	-$9.451M
YoY Change	98.35%	-44.26%	24.42%
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities		$0.00	-$3.000M
YoY Change
Cash From Investing Activities		$0.00	-$3.000M
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net			$0.00
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	$4.531M	3.946M	$7.526M
YoY Change	46.11%	-62.98%	-28.6%
NET CHANGE
Cash From Operating Activities	-$3.120M	-2.324M	-$9.451M
Cash From Investing Activities		0.000	-$3.000M
Cash From Financing Activities	$4.531M	3.946M	$7.526M
Net Change In Cash	$1.411M	1.622M	-$4.925M
YoY Change	-7.66%	-75.01%	-267.23%
FREE CASH FLOW
Cash From Operating Activities	-$3.120M	-$2.324M	-$9.451M
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2023	dei	Amendment Flag AmendmentFlag	false
CY2023	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2023	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	FY
CY2023	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2023
CY2023Q4	ecd	Rule10b51 Arr Adopted Flag Rule10b51ArrAdoptedFlag	false
CY2023Q4	ecd	Non Rule10b51 Arr Adopted Flag NonRule10b51ArrAdoptedFlag	false
CY2023Q4	ecd	Rule10b51 Arr Trmntd Flag Rule10b51ArrTrmntdFlag	false
CY2023Q4	ecd	Non Rule10b51 Arr Trmntd Flag NonRule10b51ArrTrmntdFlag	false
CY2023Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2022Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2023Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2022Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2023Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	2000000
CY2022Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	2000000
CY2023Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	250000
CY2023Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	250000
CY2022Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	250000
CY2022Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	250000
CY2023Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2023	dei	Auditor Name AuditorName	KPMG LLP
CY2023	dei	Auditor Location AuditorLocation	New York, NY
CY2023	dei	Auditor Firm AuditorFirmId	185
CY2023Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	1783000	usd
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	6708000	usd
CY2023Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	67000	usd
CY2022Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	137000	usd
CY2023Q4	us-gaap	Assets Assets	1850000	usd
CY2022Q4	us-gaap	Assets Assets	6845000	usd
CY2022Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2023Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	75000000
CY2023Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	25597622
CY2023Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	25597622
CY2022Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	20000000
CY2022Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	4773841
CY2022Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	4773841
CY2022Q4	us-gaap	Warrants And Rights Outstanding Term WarrantsAndRightsOutstandingTerm	P5Y
CY2023	us-gaap	Number Of Operating Segments NumberOfOperatingSegments	1	pure
CY2022Q4	us-gaap	Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued	0	usd
CY2023	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	usd
CY2022	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	usd
CY2023	us-gaap	Unrecognized Tax Benefits Income Tax Penalties And Interest Expense UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense	0	usd
CY2022	us-gaap	Unrecognized Tax Benefits Income Tax Penalties And Interest Expense UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense	0	usd
CY2023	dei	Document Type DocumentType	10-K
CY2023	dei	Document Annual Report DocumentAnnualReport	true
CY2023	dei	Document Period End Date DocumentPeriodEndDate	2023-12-31
CY2023	dei	Document Transition Report DocumentTransitionReport	false
CY2023	dei	Entity File Number EntityFileNumber	001-38114
CY2023	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
CY2023	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	47-4113275
CY2023	dei	Entity Address Address Line1 EntityAddressAddressLine1	1111 Kane Concourse, Suite 301
CY2023	dei	Entity Address City Or Town EntityAddressCityOrTown	Bay Harbor Islands
CY2023	dei	Entity Address State Or Province EntityAddressStateOrProvince	FL
CY2023	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	33154
CY2023	dei	City Area Code CityAreaCode	781
CY2023	dei	Local Phone Number LocalPhoneNumber	652-4500
CY2023	dei	Security12b Title Security12bTitle	Common Stock, par value $0.0001 per share
CY2023	dei	Trading Symbol TradingSymbol	ATXI
CY2023	dei	Security Exchange Name SecurityExchangeName	NASDAQ
CY2023	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	No
CY2023	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2023	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2023	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2023	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
CY2023	dei	Entity Small Business EntitySmallBusiness	true
CY2023	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2023	dei	Icfr Auditor Attestation Flag IcfrAuditorAttestationFlag	false
CY2023	dei	Document Fin Stmt Error Correction Flag DocumentFinStmtErrorCorrectionFlag	false
CY2023	dei	Entity Shell Company EntityShellCompany	false
CY2023Q2	dei	Entity Public Float EntityPublicFloat	8522013	usd
CY2024Q1	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	44260667
CY2023Q4	us-gaap	Derivative Liabilities Current DerivativeLiabilitiesCurrent	586000	usd
CY2022Q4	us-gaap	Derivative Liabilities Current DerivativeLiabilitiesCurrent	2609000	usd
CY2023Q4	us-gaap	Liabilities Current LiabilitiesCurrent	1196000	usd
CY2022Q4	us-gaap	Liabilities Current LiabilitiesCurrent	3579000	usd
CY2023Q4	us-gaap	Liabilities Liabilities	1196000	usd
CY2022Q4	us-gaap	Liabilities Liabilities	3579000	usd
CY2023Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	usd
CY2022Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	usd
CY2023Q4	us-gaap	Common Stock Value CommonStockValue	3000	usd
CY2022Q4	us-gaap	Common Stock Value CommonStockValue	0	usd
CY2023Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	92507000	usd
CY2022Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	84456000	usd
CY2023Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-90928000	usd
CY2022Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-80551000	usd
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	1582000	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	3905000	usd
CY2023Q4	us-gaap	Minority Interest MinorityInterest	-928000	usd
CY2022Q4	us-gaap	Minority Interest MinorityInterest	-639000	usd
CY2023Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	654000	usd
CY2022Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	3266000	usd
CY2023Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	1850000	usd
CY2022Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	6845000	usd
CY2023	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	6131000	usd
CY2022	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	2698000	usd
CY2023	atxi	Research And Development Expense For Licenses Acquired ResearchAndDevelopmentExpenseForLicensesAcquired	4230000	usd
CY2022	atxi	Research And Development Expense For Licenses Acquired ResearchAndDevelopmentExpenseForLicensesAcquired	0	usd
CY2023	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	4179000	usd
CY2022	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	5345000	usd
CY2023	us-gaap	Operating Income Loss OperatingIncomeLoss	-14540000	usd
CY2022	us-gaap	Operating Income Loss OperatingIncomeLoss	-8043000	usd
CY2023	us-gaap	Investment Income Interest InvestmentIncomeInterest	126000	usd
CY2022	us-gaap	Investment Income Interest InvestmentIncomeInterest	20000	usd
CY2023	atxi	Financing Costs Warrant Liabilities FinancingCostsWarrantLiabilities	332000	usd
CY2022	atxi	Financing Costs Warrant Liabilities FinancingCostsWarrantLiabilities	1160000	usd
CY2023	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	-4258000	usd
CY2022	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	-5580000	usd
CY2023	us-gaap	Profit Loss ProfitLoss	-10488000	usd
CY2022	us-gaap	Profit Loss ProfitLoss	-3603000	usd
CY2023	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	-111000	usd
CY2022	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	-51000	usd
CY2023	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-10377000	usd
CY2022	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-3552000	usd
CY2023	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.98
CY2022	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-1.63
CY2023	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	10591636
CY2022	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	2185159
CY2021Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	3451000	usd
CY2022	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	649000	usd
CY2022	atxi	Common Shares Issuable Founders Agreement CommonSharesIssuableFoundersAgreement	526000	usd
CY2022	atxi	Shares And Warrants Issued During Period Value SharesAndWarrantsIssuedDuringPeriodValue	3205000	usd
CY2022	us-gaap	Stock Repurchased And Retired During Period Value StockRepurchasedAndRetiredDuringPeriodValue	1104000	usd
CY2022	atxi	Adjustment To Additional Paid In Capital Asset Acquisitions AdjustmentToAdditionalPaidInCapitalAssetAcquisitions	-99000	usd
CY2022	atxi	Adjustment To Additional Paid In Capital Issuance Of Subsidiaries Common Shares For License Expenses AdjustmentToAdditionalPaidInCapitalIssuanceOfSubsidiariesCommonSharesForLicenseExpenses	4000	usd
CY2022	atxi	Stock Issued During Period Value Exercise0f Warrants StockIssuedDuringPeriodValueExercise0fWarrants	237000	usd
CY2022	atxi	Adjustments To Additional Paid In Capital And Noncontrolling Interest From Subsidiary Equity Issuance AdjustmentsToAdditionalPaidInCapitalAndNoncontrollingInterestFromSubsidiaryEquityIssuance	0	usd
CY2022	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	-51000	usd
CY2022	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-3552000	usd
CY2022Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	3266000	usd
CY2023	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	906000	usd
CY2023	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	72000	usd
CY2023	atxi	Common Shares Issuable Founders Agreement CommonSharesIssuableFoundersAgreement	371000	usd
CY2023	atxi	Stock And Prefunded Warrants Issued During Period Values November2023 Public Offering Net Of Issuance Costs StockAndPrefundedWarrantsIssuedDuringPeriodValuesNovember2023PublicOfferingNetOfIssuanceCosts	3874000	usd
CY2023	atxi	Shares And Warrants Issued During Period Value SharesAndWarrantsIssuedDuringPeriodValue	866000	usd
CY2023	atxi	Stock Issued During Period Value License Expense StockIssuedDuringPeriodValueLicenseExpense	1230000	usd
CY2023	atxi	Adjustment To Additional Paid In Capital Issuance Of Subsidiaries Common Shares For License Expenses AdjustmentToAdditionalPaidInCapitalIssuanceOfSubsidiariesCommonSharesForLicenseExpenses	6000	usd
CY2023	atxi	Stock Issued During Period Value Exercise0f Warrants StockIssuedDuringPeriodValueExercise0fWarrants	1000	usd
CY2023	us-gaap	Noncontrolling Interest Decrease From Deconsolidation NoncontrollingInterestDecreaseFromDeconsolidation	0	usd
CY2023	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	-111000	usd
CY2023	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-10377000	usd
CY2022Q4	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	0.01
CY2022Q4	atxi	Class Of Warrant Or Right Exercisable During Period ClassOfWarrantOrRightExercisableDuringPeriod	949900
CY2022Q4	atxi	Class Of Warrant Or Right Issued During Period ClassOfWarrantOrRightIssuedDuringPeriod	949900
CY2023Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	654000	usd
CY2023	us-gaap	Profit Loss ProfitLoss	-10488000	usd
CY2022	us-gaap	Profit Loss ProfitLoss	-3603000	usd
CY2023	us-gaap	Share Based Compensation ShareBasedCompensation	906000	usd
CY2022	us-gaap	Share Based Compensation ShareBasedCompensation	649000	usd
CY2023	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	-4258000	usd
CY2022	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	-5580000	usd
CY2023	atxi	Issuance Of Stock Under Founders Agreement IssuanceOfStockUnderFoundersAgreement	371000	usd
CY2022	atxi	Issuance Of Stock Under Founders Agreement IssuanceOfStockUnderFoundersAgreement	526000	usd
CY2023	atxi	Common Stock Issued To Fortress Value CommonStockIssuedToFortressValue	72000	usd
CY2022	atxi	Common Stock Issued To Fortress Value CommonStockIssuedToFortressValue	0	usd
CY2023	atxi	Issuance Of Stock For Licenses Acquired IssuanceOfStockForLicensesAcquired	1230000	usd
CY2022	atxi	Issuance Of Stock For Licenses Acquired IssuanceOfStockForLicensesAcquired	0	usd
CY2023	atxi	Research And Development License Acquried Expense ResearchAndDevelopmentLicenseAcquriedExpense	3000000	usd
CY2022	atxi	Research And Development License Acquried Expense ResearchAndDevelopmentLicenseAcquriedExpense	0	usd
CY2023	atxi	License Expenses Paid In Kind LicenseExpensesPaidInKind	6000	usd
CY2022	atxi	License Expenses Paid In Kind LicenseExpensesPaidInKind	4000	usd
CY2023	us-gaap	Increase Decrease In Due From Other Related Parties Current IncreaseDecreaseInDueFromOtherRelatedPartiesCurrent	-0	usd
CY2022	us-gaap	Increase Decrease In Due From Other Related Parties Current IncreaseDecreaseInDueFromOtherRelatedPartiesCurrent	-90000	usd
CY2023	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-70000	usd
CY2022	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	30000	usd
CY2023	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-9451000	usd
CY2022	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-7596000	usd
CY2023	atxi	Payments To Acquire Research And Development Licenses PaymentsToAcquireResearchAndDevelopmentLicenses	3000000	usd
CY2022	atxi	Payments To Acquire Research And Development Licenses PaymentsToAcquireResearchAndDevelopmentLicenses	-0	usd
CY2023	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-3000000	usd
CY2022	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	0	usd
CY2023	atxi	Issuance Of Common Stock Prefund Warrants And Warrants IssuanceOfCommonStockPrefundWarrantsAndWarrants	7525000	usd
CY2022	atxi	Issuance Of Common Stock Prefund Warrants And Warrants IssuanceOfCommonStockPrefundWarrantsAndWarrants	11497000	usd
CY2023	us-gaap	Payments For Repurchase Of Common Stock PaymentsForRepurchaseOfCommonStock	-0	usd
CY2022	us-gaap	Payments For Repurchase Of Common Stock PaymentsForRepurchaseOfCommonStock	1104000	usd
CY2023	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	1000	usd
CY2022	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	148000	usd
CY2023	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	7526000	usd
CY2022	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	10541000	usd
CY2023	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	-4925000	usd
CY2022	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	2945000	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	6708000	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	3763000	usd
CY2023Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	1783000	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	6708000	usd
CY2023	us-gaap	Fair Value Of Assets Acquired FairValueOfAssetsAcquired	0	usd
CY2022	us-gaap	Fair Value Of Assets Acquired FairValueOfAssetsAcquired	99000	usd
CY2023	atxi	Unpaid Offering Costs UnpaidOfferingCosts	0	usd
CY2022	atxi	Unpaid Offering Costs UnpaidOfferingCosts	14000	usd
CY2022Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	50000000
CY2022Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	20000000
CY2023Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	20000000
CY2023Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	75000000
CY2022Q4	atxi	Percentage Of Warrants Issued PercentageOfWarrantsIssued	0.15	pure
CY2022Q4	us-gaap	Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights	545454
CY2022Q4	atxi	Percentage Of Warrants Issued PercentageOfWarrantsIssued	0.15	pure
CY2022Q4	us-gaap	Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights	545454
CY2022Q4	atxi	Net Proceeds From Issuance Initial Public Offering NetProceedsFromIssuanceInitialPublicOffering	10.3	usd
CY2023Q3	us-gaap	Proceeds From Issuance Of Private Placement ProceedsFromIssuanceOfPrivatePlacement	600000	usd
CY2023Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2023Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-90900000	usd
CY2023	us-gaap	Number Of Reportable Segments NumberOfReportableSegments	1	pure
CY2023	us-gaap	Use Of Estimates UseOfEstimates	<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i>Use of Estimates</i></b></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">The preparation of consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of expenses during the reporting period. Actual results could differ from those estimates.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p>
CY2016Q3	us-gaap	Stock Issued During Period Shares New Issues StockIssuedDuringPeriodSharesNewIssues	250000
CY2016Q3	us-gaap	Preferred Stock Dividend Rate Percentage PreferredStockDividendRatePercentage	0.025	pure
CY2023	atxi	Research And Development Expense Licenses Acquired ResearchAndDevelopmentExpenseLicensesAcquired	300000	usd
CY2023Q1	us-gaap	Common Stock Dividends Shares CommonStockDividendsShares	231316
CY2022	atxi	Research And Development Expense Licenses Acquired ResearchAndDevelopmentExpenseLicensesAcquired	300000	usd
CY2023	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	43246230
CY2022	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	4489944
CY2023Q4	us-gaap	Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued	0	usd
CY2019Q4	atxi	Contractual Obligation Development Expense ContractualObligationDevelopmentExpense	81500000	usd
CY2019Q4	atxi	Contractual Obligation Commercial Expense ContractualObligationCommercialExpense	151000000	usd
CY2023Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	78000	usd
CY2022Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	129000	usd
CY2023Q4	us-gaap	Accrued Employee Benefits Current AccruedEmployeeBenefitsCurrent	11000	usd
CY2022Q4	us-gaap	Accrued Employee Benefits Current AccruedEmployeeBenefitsCurrent	199000	usd
CY2023Q4	atxi	Accrued Contingent Fee AccruedContingentFee	0	usd
CY2022Q4	atxi	Accrued Contingent Fee AccruedContingentFee	208000	usd
CY2023Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	198000	usd
CY2022Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	413000	usd
CY2016Q3	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	2000000
CY2023Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	55000000
CY2023Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	75000000
CY2023Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2023Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	25597622
CY2022Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	20000000
CY2022Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	4773841
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber	94418
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue	56.25
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeited In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod	666
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeitures Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue	13.95
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod	80615
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue	40.83
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber	13137
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue	12.17
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod	85000
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	1.14
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber	98137
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue	12.17
CY2023	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	906000	usd
CY2022	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	649000	usd
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	0
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	0
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	0	usd
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	0
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	0
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	0	usd
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	1685000000
CY2023	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	1.14
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	1685000000
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	1.14
CY2023	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P9Y6M
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	0	usd
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber	262500000
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice	1.14
CY2023	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1	P9Y6M
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Aggregate Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue	0	usd
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.0414	pure
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0	pure
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0	pure
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0	pure
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	1.2572	pure
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	0	pure
CY2021Q4	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	997
CY2021Q4	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	9.98
CY2022	atxi	Class Of Warrant Or Right Aggregate Intrinsic Value ClassOfWarrantOrRightAggregateIntrinsicValue	11000	usd
CY2022	atxi	Class Of Warrant Or Right Issued During Period ClassOfWarrantOrRightIssuedDuringPeriod	5166119
CY2022	atxi	Class Of Warrant Or Right Granted During Period Exercise Price Of Warrants Or Rights ClassOfWarrantOrRightGrantedDuringPeriodExercisePriceOfWarrantsOrRights	2.67
CY2022	atxi	Class Of Warrant Or Right Exercised During Period ClassOfWarrantOrRightExercisedDuringPeriod	1029200
CY2022	atxi	Class Of Warrant Or Right Exercised During Period Exercise Price Of Warrants Or Rights ClassOfWarrantOrRightExercisedDuringPeriodExercisePriceOfWarrantsOrRights	0.14
CY2022Q4	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	4137916
CY2022Q4	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	1.55
CY2023	atxi	Class Of Warrant Or Right Aggregate Intrinsic Value ClassOfWarrantOrRightAggregateIntrinsicValue	1000	usd
CY2023	atxi	Class Of Warrant Or Right Issued During Period ClassOfWarrantOrRightIssuedDuringPeriod	49479398
CY2023	atxi	Class Of Warrant Or Right Granted During Period Exercise Price Of Warrants Or Rights ClassOfWarrantOrRightGrantedDuringPeriodExercisePriceOfWarrantsOrRights	0.26
CY2023	atxi	Class Of Warrant Or Right Exercised During Period ClassOfWarrantOrRightExercisedDuringPeriod	14272382
CY2023	atxi	Class Of Warrant Or Right Exercised During Period Exercise Price Of Warrants Or Rights ClassOfWarrantOrRightExercisedDuringPeriodExercisePriceOfWarrantsOrRights	0
CY2023Q4	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	39344932
CY2023Q4	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	0.49
CY2023	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.21	pure
CY2022	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.21	pure
CY2023	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.11	pure
CY2022	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.10	pure
CY2023	atxi	Effective Income Tax Rate Reconciliation Change In Enacted State Tax Rate Percent EffectiveIncomeTaxRateReconciliationChangeInEnactedStateTaxRatePercent	0.01	pure
CY2022	atxi	Effective Income Tax Rate Reconciliation Change In Enacted State Tax Rate Percent EffectiveIncomeTaxRateReconciliationChangeInEnactedStateTaxRatePercent	-0.01	pure
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense Share Based Compensation Cost EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost	0	pure
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense Share Based Compensation Cost EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost	-0.22	pure
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Other Adjustments EffectiveIncomeTaxRateReconciliationOtherAdjustments	0	pure
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Other Adjustments EffectiveIncomeTaxRateReconciliationOtherAdjustments	0.03	pure
CY2023	atxi	Effective Income Tax Rate Reconciliation Tax Carryforward Credit Percent EffectiveIncomeTaxRateReconciliationTaxCarryforwardCreditPercent	0.01	pure
CY2022	atxi	Effective Income Tax Rate Reconciliation Tax Carryforward Credit Percent EffectiveIncomeTaxRateReconciliationTaxCarryforwardCreditPercent	0.04	pure
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense EffectiveIncomeTaxRateReconciliationNondeductibleExpense	-0.01	pure
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense EffectiveIncomeTaxRateReconciliationNondeductibleExpense	-0.11	pure
CY2023	atxi	Effective Income Tax Rate Reconciliation Section162m Disallowance Limit On Compensation EffectiveIncomeTaxRateReconciliationSection162mDisallowanceLimitOnCompensation	0	pure
CY2022	atxi	Effective Income Tax Rate Reconciliation Section162m Disallowance Limit On Compensation EffectiveIncomeTaxRateReconciliationSection162mDisallowanceLimitOnCompensation	-0.03	pure
CY2023	atxi	Effective Income Tax Rate Reconciliation Change In Fair Market Value Of Warrant EffectiveIncomeTaxRateReconciliationChangeInFairMarketValueOfWarrant	0.12	pure
CY2022	atxi	Effective Income Tax Rate Reconciliation Change In Fair Market Value Of Warrant EffectiveIncomeTaxRateReconciliationChangeInFairMarketValueOfWarrant	0.48	pure
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.45	pure
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.49	pure
CY2023	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0	pure
CY2022	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0	pure
CY2023Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	27318000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	25660000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits	287000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits	42000	usd
CY2023Q4	us-gaap	Deferred Tax Assets In Process Research And Development DeferredTaxAssetsInProcessResearchAndDevelopment	2884000	usd
CY2022Q4	us-gaap	Deferred Tax Assets In Process Research And Development DeferredTaxAssetsInProcessResearchAndDevelopment	1603000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals	4000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals	64000	usd
CY2023Q4	atxi	Deferred Tax Assets Business Interest Expense Disallowance DeferredTaxAssetsBusinessInterestExpenseDisallowance	0	usd
CY2022Q4	atxi	Deferred Tax Assets Business Interest Expense Disallowance DeferredTaxAssetsBusinessInterestExpenseDisallowance	122000	usd
CY2023Q4	atxi	Deferred Tax Assets Section174 Capitalization DeferredTaxAssetsSection174Capitalization	2253000	usd
CY2022Q4	atxi	Deferred Tax Assets Section174 Capitalization DeferredTaxAssetsSection174Capitalization	622000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards DeferredTaxAssetsTaxCreditCarryforwards	2926000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards DeferredTaxAssetsTaxCreditCarryforwards	2859000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	35672000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	30972000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	35672000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	30972000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet	0	usd
CY2022Q4	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet	0	usd
CY2023Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	35700000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	31000000	usd
CY2023Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	75000000

Files In Submission

Name	View Source	Status
0001437749-24-008294-index-headers.html	Edgar Link	pending
0001437749-24-008294-index.html	Edgar Link	pending
0001437749-24-008294.txt	Edgar Link	pending
0001437749-24-008294-xbrl.zip	Edgar Link	pending
atxi-20231231.xsd	Edgar Link	pending
atxi20221231_10k.htm	Edgar Link	pending
ex_597578.htm	Edgar Link	pending
ex_597579.htm	Edgar Link	pending
ex_597581.htm	Edgar Link	pending
ex_597582.htm	Edgar Link	pending
ex_597583.htm	Edgar Link	pending
ex_597584.htm	Edgar Link	pending
ex_631260.htm	Edgar Link	pending
ex_635063.htm	Edgar Link	pending
ex_640800.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
ksig.jpg	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
atxi-20231231_def.xml	Edgar Link	unprocessable
atxi-20231231_lab.xml	Edgar Link	unprocessable
atxi-20231231_pre.xml	Edgar Link	unprocessable
FilingSummary.xml	Edgar Link	unprocessable
atxi20221231_10k_htm.xml	Edgar Link	completed
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
atxi-20231231_cal.xml	Edgar Link	unprocessable

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$ATXI
Avenue Therapeutics Inc Stock $atxi

2024 Q1 Form 10-K Financial Statement

#000143774924008294 Filed on March 18, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$ATXI Avenue Therapeutics Inc Stock $atxi

2024 Q1 Form 10-K Financial Statement

#000143774924008294 Filed on March 18, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$ATXI
Avenue Therapeutics Inc Stock $atxi